Table 3.
Ref.
|
Method
|
Antibiotic
|
Dosing regimen
|
Diversity
|
Compositional changes
|
Pallav et al[136], 2014 | Pyrosequencing | Amoxicillin | 250 mg 3 times daily for 7 d | −1,2 | ↑ Escherichia, Shigella |
Kabbani et al[137], 2017 | 16S rRNA | Amoxicillin-Clavulanate | 875/125 mg twice daily for 7 d | ↓1,3 | ↑ Escherichia, Parabacteroides, Enterobacter ↓ Roseburia |
Burdet et al[120], 2019 | 16S rRNA | Ceftriaxone | 1 g once daily for 3 d | ↓1,4 | ↓ Firmicutes, Actinobacteria, Bacteroidetes |
Raymond et al[135], 2016 | Shotgun sequencing | Cefprozil | 500 mg twice daily for 7 d | ↓5 | ↑Flavonifractor, Lachnoclostridium, Parabacteroides, ↓Bifidobacteriaceae, Coriobacteriaceae, Eubacteriaceae, Oxalobacteraceae, Pasteurellaceae, Veillonellaceae |
Rashid et al[121], 2015 | Pyrosequencing | Ciprofloxacin | 500 mg twice daily for 10 d | ↓1 | ↑ Bacteroides↓ Faecalibacterium, Alistipes, unculturable Ruminococcaceae |
Clindamycin | 150 mg 4 times daily for 10 d | ↓1 | ↓ Roseburia, Lachospira, Coprococcus, Dorea, Ruminococcus | ||
Isaac et al[122], 2017 | 16S rRNA | Vancomycin | 250 mg per os 4 times daily for 2 wk | ↓1,4 | ↑ Escherichia, Shigella, Klebsiella, ↓ Bacteroidetes, Faecalibacterium, Ruminococcus |
OTU analysis.
Rarefaction analysis.
Chao1 index.
Shannon index.
Simpson index.